Pain
Conditions
Keywords
Safety, tolerability
Brief summary
The primary aim for this study is to investigate the safety and tolerability of the AZD1704, first time in man.
Interventions
DRUGAZD1704
One dose, by mouth
Sponsors
AstraZeneca
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
20 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
* Healthy volunteers, man or woman of non child-bearing potential * Provision of signed informed consent.
Exclusion criteria
* History of somatic disease/condition that may interfere with the objectives ot the study, as judged by the Investigator. History of seizures, with the exception of single occasions fever induced seizures in childhood. * History of previous or ongoing psychiatric disease/condition including psychosis, affective disorder, anxiety disorder, borderline state and personality disorder according to the criteria in the DSM of Mental Disorder, 4th edition * History of use of antipsychotic, antidepressant or anxiolytic drugs for the treatment of psychiatric disease or symptoms, prescribed as well as non-prescribed use.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To investigate the safety and tolerability of AZD1704 following single ascending doses in healthy volunteers. | At screening, during residential period (daily) and at follow-up |
Secondary
| Measure | Time frame |
|---|---|
| To investigate the subjective CNS effects of specific adjectives (stimulated, anxious, sedated, down and high) rated on visual analogue mood scale (VAMS). | During residential period (daily) |
Countries
United Kingdom
Outcome results
None listed